SOURCE-LINKED STUDY SUMMARY
What is the pipeline for future medications for obesity?
Abstract summarizedQuality not appraised
- What was studied
- Review of current and pipeline obesity medicines, emphasizing GLP-1 and combinations with GIP, glucagon, or amylin. It does not report one intervention, comparator, or follow-up period.
- Who / model studied
- Literature review with no enrolled population, species, or sample size reported in the abstract.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The review reports mean weight loss of 15-17% with semaglutide 2.4 mg and up to 22.5% in phase 3 tirzepatide obesity trials. CagriSema and retatrutide had reached phase 3; early data were described as potentially exceeding tirzepatide, not as a direct comparative result.
- Limitations & context
- The abstract gives no review-selection methods, study counts, or formal quality assessment. Its statement that early pipeline data may exceed tirzepatide is not a head-to-head finding, so methodological quality remains unassessed.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41366-024-01473-y